{"meshTags":["Breast Neoplasms","Chemotherapy, Adjuvant","Female","Humans","France","Receptor, ErbB-2","Antineoplastic Agents","Antibodies, Monoclonal"],"meshMinor":["Breast Neoplasms","Chemotherapy, Adjuvant","Female","Humans","France","Receptor, ErbB-2","Antineoplastic Agents","Antibodies, Monoclonal"],"publicationTypes":["Journal Article"],"abstract":"An improvement in survival time, but cardiotoxicity remains a concern.","title":"Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.","pubmedId":"17582927"}